Catalent Inc (NYSE:CTLT) has earned an average recommendation of “Buy” from the fourteen research firms that are presently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation and nine have given a buy recommendation to the company. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is $49.71.

Several equities analysts have recently commented on the company. Zacks Investment Research raised Catalent from a “hold” rating to a “buy” rating and set a $48.00 price target on the stock in a research note on Monday, July 9th. JPMorgan Chase & Co. boosted their price objective on Catalent from $50.00 to $55.00 and gave the company an “overweight” rating in a report on Wednesday, August 29th. Finally, ValuEngine upgraded Catalent from a “hold” rating to a “buy” rating in a report on Tuesday, June 26th.

NYSE CTLT traded up $1.16 on Friday, reaching $45.30. 894,317 shares of the company were exchanged, compared to its average volume of 952,847. The firm has a market capitalization of $6.30 billion, a P/E ratio of 28.26, a price-to-earnings-growth ratio of 2.58 and a beta of 1.42. The company has a debt-to-equity ratio of 2.44, a quick ratio of 1.79 and a current ratio of 2.15. Catalent has a fifty-two week low of $36.73 and a fifty-two week high of $47.87.

Catalent (NYSE:CTLT) last announced its quarterly earnings results on Tuesday, August 28th. The company reported $0.67 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.61 by $0.06. Catalent had a return on equity of 20.42% and a net margin of 3.39%. The business had revenue of $685.30 million for the quarter, compared to analyst estimates of $690.69 million. During the same quarter in the prior year, the company posted $0.65 EPS. The company’s quarterly revenue was up 11.1% on a year-over-year basis. sell-side analysts forecast that Catalent will post 1.72 EPS for the current year.

In other news, Director Donald E. Morel, Jr. acquired 10,000 shares of the business’s stock in a transaction that occurred on Thursday, September 13th. The shares were purchased at an average price of $43.00 per share, for a total transaction of $430,000.00. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. 1.70% of the stock is currently owned by insiders.

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Oregon Public Employees Retirement Fund increased its holdings in Catalent by 2.6% during the 2nd quarter. Oregon Public Employees Retirement Fund now owns 51,962 shares of the company’s stock worth $2,177,000 after purchasing an additional 1,299 shares during the period. United Services Automobile Association increased its holdings in Catalent by 6.4% during the 2nd quarter. United Services Automobile Association now owns 23,725 shares of the company’s stock worth $994,000 after purchasing an additional 1,418 shares during the period. Mason Street Advisors LLC increased its holdings in Catalent by 2.3% during the 1st quarter. Mason Street Advisors LLC now owns 66,961 shares of the company’s stock worth $2,749,000 after purchasing an additional 1,505 shares during the period. Russell Investments Group Ltd. increased its holdings in Catalent by 3.6% during the 2nd quarter. Russell Investments Group Ltd. now owns 45,738 shares of the company’s stock worth $1,915,000 after purchasing an additional 1,578 shares during the period. Finally, Municipal Employees Retirement System of Michigan increased its holdings in Catalent by 4.3% during the 1st quarter. Municipal Employees Retirement System of Michigan now owns 41,420 shares of the company’s stock worth $1,701,000 after purchasing an additional 1,690 shares during the period. Institutional investors own 91.96% of the company’s stock.

About Catalent

Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel Technologies, Biologics and Specialty Drug Delivery, Oral Drug Delivery, and Clinical Supply Services. The Softgel Technologies segment formulates, develops, and manufactures prescription and consumer soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations.

Further Reading: How Do You Calculate Return on Investment (ROI)?

Analyst Recommendations for Catalent (NYSE:CTLT)

Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.